The Bewildering Antitubercular Action of Pyrazinamide | Zendy

Elise A. Lamont | Zendy; Nicholas Dillon | Zendy; Anthony D. Baughn | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The Bewildering Antitubercular Action of Pyrazinamide

Author(s) -

Elise A. Lamont,

Nicholas Dillon,

Anthony D. Baughn

Publication year - 2020

Publication title -

microbiology and molecular biology reviews

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.358

H-Index - 247

eISSN - 1098-5557

pISSN - 1092-2172

DOI - 10.1128/mmbr.00070-19

Subject(s) - pyrazinamide , tuberculosis , drug , biology , mycobacterium tuberculosis , pharmacology , pharmacotherapy , first line , drug action , disease , bedaquiline , intensive care medicine , medicine , pathology

Pyrazinamide (PZA) is a cornerstone antimicrobial drug used exclusively for the treatment of tuberculosis (TB). Due to its ability to shorten drug therapy by 3 months and reduce disease relapse rates, PZA is considered an irreplaceable component of standard first-line short-course therapy for drug-susceptible TB and second-line treatment regimens for multidrug-resistant TB. Despite over 60 years of research on PZA and its crucial role in current and future TB treatment regimens, the mode of action of this unique drug remains unclear.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research